X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dabigatran (1569) 1569
index medicus (1505) 1505
humans (1486) 1486
anticoagulants (966) 966
warfarin (947) 947
rivaroxaban (943) 943
dabigatran etexilate (669) 669
administration, oral (630) 630
atrial fibrillation (627) 627
apixaban (603) 603
anticoagulants - therapeutic use (593) 593
anticoagulants - administration & dosage (503) 503
anticoagulants - adverse effects (475) 475
male (475) 475
stroke (466) 466
venous thromboembolism (456) 456
pharmacokinetics (454) 454
hematology (447) 447
female (442) 442
atrial fibrillation - drug therapy (423) 423
pharmacology & pharmacy (423) 423
atrial-fibrillation (410) 410
prevention (395) 395
aged (394) 394
direct thrombin inhibitor (386) 386
peripheral vascular disease (372) 372
cardiac & cardiovascular systems (354) 354
thromboembolism (353) 353
hemorrhage - chemically induced (348) 348
thrombin (345) 345
beta-alanine - analogs & derivatives (336) 336
stroke - prevention & control (336) 336
pharmacodynamics (316) 316
risk factors (303) 303
middle aged (290) 290
atrial fibrillation - complications (286) 286
benzimidazoles - therapeutic use (262) 262
anticoagulants - pharmacokinetics (260) 260
medicine & public health (260) 260
safety (259) 259
treatment outcome (252) 252
stroke prevention (241) 241
benzimidazoles - adverse effects (239) 239
anticoagulation (238) 238
drug therapy (232) 232
blood coagulation - drug effects (226) 226
edoxaban (222) 222
management (221) 221
benzimidazoles - administration & dosage (217) 217
bleeding (217) 217
oral anticoagulants (210) 210
cardiac arrhythmia (207) 207
medicine, general & internal (207) 207
analysis (203) 203
thrombosis (203) 203
aged, 80 and over (197) 197
care and treatment (196) 196
factor xa inhibitor (191) 191
therapy (191) 191
factor xa inhibitors (186) 186
pyrazoles - therapeutic use (184) 184
pyridones - therapeutic use (184) 184
cardiology (183) 183
antithrombins - adverse effects (182) 182
stroke - etiology (181) 181
anticoagulants - pharmacology (176) 176
abridged index medicus (175) 175
etexilate (175) 175
factor-xa inhibitor (172) 172
animals (170) 170
warfarin - therapeutic use (170) 170
pyridines - therapeutic use (167) 167
risk (167) 167
double-blind (166) 166
beta-alanine - adverse effects (163) 163
dosage and administration (163) 163
surgery (162) 162
hemorrhage (161) 161
patients (161) 161
reversal (161) 161
benzimidazoles - pharmacokinetics (158) 158
beta-alanine - therapeutic use (155) 155
direct oral anticoagulants (155) 155
antithrombins - therapeutic use (153) 153
enoxaparin (150) 150
internal medicine (150) 150
drug interactions (147) 147
dose-response relationship, drug (144) 144
antithrombotic therapy (143) 143
prothrombin complex concentrate (143) 143
thiophenes - therapeutic use (143) 143
venous thromboembolism - prevention & control (142) 142
morpholines - therapeutic use (141) 141
thromboembolism - prevention & control (141) 141
vitamin k - antagonists & inhibitors (141) 141
antithrombins - administration & dosage (138) 138
dabigatran - therapeutic use (138) 138
adult (137) 137
nonvalvular atrial-fibrillation (137) 137
dabigatran - adverse effects (136) 136
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2001) 2001
German (55) 55
French (29) 29
Spanish (21) 21
Russian (9) 9
Portuguese (2) 2
Arabic (1) 1
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Japanese (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 24, pp. 2888 - 2899
... dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | CARDIAC & CARDIOVASCULAR SYSTEMS | APPENDAGE CLOSURE | PLATELET-AGGREGATION | SAFETY | PHARMACOKINETICS | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | HEMODIALYSIS-PATIENTS | NONVALVULAR ATRIAL-FIBRILLATION | STAGE RENAL-DISEASE | WARFARIN USE | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages
Journal Article
Journal Article
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2013, Volume 29, Issue 7, pp. S24 - S33
... variability in response, unpredictable pharmacokinetic characteristics (PK), drug-drug interactions, and polymorphisms in genes affecting metabolism and pharmacodynamic... 
Cardiovascular | IN-VITRO | CARDIAC & CARDIOVASCULAR SYSTEMS | DIRECT THROMBIN INHIBITOR | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | VENOUS THROMBOEMBOLISM | STROKE PREVENTION | ASSAYS LABORATORY RECOMMENDATIONS | ORAL BIOAVAILABILITY | NONVALVULAR ATRIAL-FIBRILLATION | COAGULATION ASSAYS | Anticoagulants - administration & dosage | Outcome Assessment (Health Care) | Thiophenes - adverse effects | Humans | beta-Alanine - pharmacokinetics | Warfarin - adverse effects | Biological Availability | Thiophenes - administration & dosage | Dabigatran | Drug Monitoring - methods | Warfarin - administration & dosage | Patient Selection | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Drug Interactions | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Pyrazoles - pharmacokinetics | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Pyrazoles - adverse effects | Stroke - prevention & control | beta-Alanine - adverse effects | Pyridones - pharmacokinetics | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Polymorphism, Genetic | Warfarin - pharmacokinetics | Atrial Fibrillation - blood | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Stroke - etiology | Blood Coagulation - drug effects | Blood Coagulation - genetics | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Pyridones - adverse effects
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for clinical use... 
GAMMA-CARBOXYGLUTAMIC ACID | INTRAVENOUS PHYTONADIONE VITAMIN-K-1 | FACTOR-XA INHIBITOR | VENOUS LIMB GANGRENE | EUROPEAN CONCERTED ACTION | LOW-INTENSITY WARFARIN | RESPIRATORY SYSTEM | VITAMIN-K ANTAGONISTS | TOTAL HIP-REPLACEMENT | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
by M. Ufer
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2010, Volume 103, Issue 3, pp. 572 - 585
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 5, pp. 552 - 560
fondaparinux | CARDIAC & CARDIOVASCULAR SYSTEMS | bivalirudin | STROKE PREVENTION | myocardial infarction | INITIAL TREATMENT | heparin | ST-ELEVATION | PERCUTANEOUS CORONARY INTERVENTION | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | anticoagulants | mortality | ACUTE MYOCARDIAL-INFARCTION | PERIPHERAL VASCULAR DISEASE | enoxaparin | NONVALVULAR ATRIAL-FIBRILLATION | Fibrinolytic Agents - classification | Recombinant Proteins - therapeutic use | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Benzylamines - adverse effects | Factor Xa Inhibitors | Anticoagulants - classification | Humans | Thrombin - antagonists & inhibitors | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - therapeutic use | Fibrinolytic Agents - adverse effects | Rivaroxaban | Pyridines - adverse effects | Angina, Unstable - drug therapy | Prothrombin - antagonists & inhibitors | Hirudins - pharmacokinetics | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Polysaccharides - therapeutic use | Azetidines - adverse effects | Peptide Fragments - pharmacokinetics | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Forecasting | Azetidines - therapeutic use | Brain Ischemia - drug therapy | Peptide Fragments - therapeutic use | Benzylamines - pharmacokinetics | Hemorrhage - chemically induced | Heparin - therapeutic use | Recombinant Proteins - pharmacokinetics | Dabigatran | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Thrombophilia - drug therapy | Pyridines - therapeutic use | Azetidines - pharmacokinetics | Clinical Trials as Topic | Coumarins - therapeutic use | Polysaccharides - pharmacology | Thiophenes - pharmacokinetics | Myocardial Infarction - drug therapy | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Benzylamines - therapeutic use | Physiological aspects | Usage | Warfarin | Heparin
Journal Article
Journal Article
American Heart Journal, ISSN 0002-8703, 2012, Volume 163, Issue 6, pp. 931 - 937.e1
Journal Article